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Abstract
Evidence indicates that autoimmunity can be triggered by virus-specific CD8+ T-cells that crossreact with self-
derived peptide epitopes presented on the cell surface by major histocompatibility complex class I (MHCI) molecules.
Identification of the associated viral pathogens is challenging because individual T-cell receptors (TCRs) can poten-
tially recognize up to a million different peptides. Here, we generate peptide length-matched combinatorial peptide
library (CPL) scan data for a panel of virus-specific CD8+ T-cell clones spanning different restriction elements
and a range of epitope lengths. CPL scan data drove a protein database search, restricted to viruses that infect
humans. Peptide sequences were ranked in order of likelihood recognition. For all anti-viral CD8+ T-cell clones
examined, the index peptide was either the top-ranked sequence or ranked as one of the most likely sequences to
be recognized. Thus, we demonstrate that anti-viral CD8+ T-cell clones are highly focused on their index peptide
sequence and that “CPL-driven database searching” can be used to identify the inciting virus-derived epitope for
a given CD8+ T-cell clone. Moreover, to augment access to CPL-driven database searching, we have created a
publicly accessible webtool. Application of these methodologies in the clinical setting may clarify the role of viral
pathogens in the etiology of autoimmune diseases.
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Introduction
CD8+ T-cells recognize antigens in the form of intracellular protein-derived peptide fragments (8–14 amino acids in
length) presented on the cell surface by major histocompatibility complex class I (MHCI) molecules. Although this
modus operandi enables the elimination of cancerous or infected cells, dysregulated CD8+ T-cell immunity can have
devastating consequences for the host. For example, it has been proposed that CD8+ T-cells play a major role in the
pathogenesis of common autoimmune diseases, such as type I diabetes,1,2,3 multiple sclerosis,4 and psoriasis,5 where
pathogen-derived peptide sequences are thought to drive the expansion of self-reactive T-cells capable of mediating
autoimmune attack.6,7 This theory is supported by findings that microbial peptides can induce experimental autoim-
mune disease in mouse models and that human autoantigen-specific T-cells can recognize numerous peptides, some
of which are microbial in origin.8,9 Moreover, in certain disease states, the presence of monoclonal/oligoclonal CD8+
T-cell expansions with a late differentiation phenotype, sometimes referred to as large granular lymphocytes (LGLs),
is suggestive of an exaggerated antigen-specific response.10 CD8+ T-LGL expansions are a characteristic feature of
LGL leukemia11,12,13 and can be triggered by certain drugs, notably protein tyrosine kinase inhibitors.14,15 CD8+
T-cell expansions are also observed in autoimmune diseases such as rheumatoid arthritis16 and aplastic anaemia.17
It is possible that viral antigens drive these pathogenic CD8+ T-cell expansions, which subsequently crossreact with
self-derived peptide-MHCI (pMHCI) molecules to precipitate clinical disease.
Although it is clear that CD8+ T-cells play an important role in health and disease, relatively little is known about
the microbial and self-derived ligands involved in these processes. This lack of knowledge can to a large extent be
attributed to the complexity of the peptide repertoire recognized by individual T-cell receptors (TCRs). Estimates
suggest that there are ∼ 25 million unique T-cell receptors in the human TCR repertoire,18 each with the potential
to recognize up to one million different MHC-bound peptides.19,20 Such promiscuous recognition has been deemed
essential for effective immunity, as a relatively limited repertoire of TCRs must provide adequate coverage against
a vast array of different pMHCI molecules.21 Indeed, a given TCR may not only interact productively with ligands
similar to the index peptide that triggered the initial response, but also with ligands that are unrelated in sequence,22
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indicating that effective characterization of the cognate ligand repertoire must take the entire peptide universe into
account without bias. A promising approach that satisfies these desiderata is combinatorial peptide library (CPL)
scanning which can be combined with biometrical analysis to identify naturally occurring ligands.23,24
Although the set of peptides recognized by an individual TCR can be vast, not all of these sequences will be present
in the naturally occurring MHCI-presentable peptide repertoire. Novel approaches are therefore required to identify
biologically relevant ligands. Ideally, such an approach should incorporate: (i) an assessment of peptide length
specificity;25 (ii) an unbiased framework applicable to all TCRs irrespective of specificity and MHCI restriction;
(iii) rapid throughput for clinical applicability; and (iv) an accurate end point for the reliable classification of response-
evoking ligands in vivo.
Here, we develop and validate a strategy to examine the peptide repertoire recognized by individual TCRs. Raw
datasets from length-matched CPL scans were used to rank peptides occurring in curated databases of viral pathogen
or human self origin. The predictive value of the scoring method was then validated by measuring functional sensi-
tivity for a selection of peptides spanning a range of predicted agonist likelihood values. This approach enabled us to
identify the original viral determinant for a CD8+ T-cell response. We envisage that “CPL-driven database searching”
will find clinical utility across a range of immune-mediated diseases with currently unknown antigenic triggers.
Results
Development and validation of an effective approach to identify natural ligands recognized by indi-
vidual MHCI-restricted TCRs
Pathogenic CD8+ T-cell expansions may originate as an initially protective response to a viral antigen that results
in immune-mediated disease, caused by subsequent crossreactivity with a self-derived pMHCI molecule. The need
therefore arises to identify viral ligands that trigger CD8+ T-cell expansions of unknown specificity. To develop and
validate an approach to this problem, we interrogated a CD8+ T-cell clone (E7NLV) specific for the immunodominant
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HLA A*0201-restricted human cytomegalovirus (HCMV) pp65495−503 epitope NLVPMVATV; HCMV is a member of
the herpesvirus family that has been implicated in the pathogenesis of common CD8+ T-cell-mediated diseases.26
MHCI-restricted TCRs display an explicit preference for peptide length, as attested by the fact that screening
with CPLs of non-preferred length elicits a minute number of positive responses, whereas screening with CPLs of
the preferred length elicits responses at every peptide position, allowing the molecular recognition landscape for each
individual TCR to be mapped in detail.25 Accordingly, we scanned E7NLV with a nonamer CPL to determine the
amino acid preferences across the peptide backbone. Multiple responses were observed at the majority of positions,
indicative of a crossreactive TCR with a propensity for degenerate peptide recognition (Figure 1). Although CPL scan
data can be used to perform BLAST or motif-based searches directly, these approaches generate peptide lists without
quantifying the likelihood of recognition. We took an alternative approach that uses raw peptide length-matched CPL
scan data to search large protein databases, producing lists of potential peptide agonists ranked in order of likelihood
of recognition. This ranking was achieved by assigning an agonist likelihood score Λ, as defined by eqn (8), to each
subsequence in a protein database comprising the majority of known viruses regardless of host tropism.
To validate the accuracy of this approach, thirty peptide sequences were chosen by uniform sampling without rep-
etition such that their Λ-values spanned approximately six orders of magnitude. Sampling was implemented using the
MATLAB datasample command; when there were five different peptides in each bin for a given order of magni-
tude, the sampling algorithm halted. The peptides were synthesized and a functional sensitivity assay was performed.
Figure 2a shows the functional response of E7NLV to the thirty selected peptides. A broad range of recognition was
observed, with 15 out of 30 peptides acting as good agonists and 6 out of 30 peptides acting as strong agonists (Figure
2a). The functional sensitivity of the clone for each peptide was expressed as pEC50, the common cologarithm of the
50%-efficacy concentration. Relative functional sensitivity (∆pEC50) was calculated by subtracting the pEC50 of the
index peptide from the pEC50 of the given peptide (Figure 2b). We examined the statistical dependence between Λ
and ∆pEC50 for all thirty randomly chosen peptides using Spearman’s rank correlation test. The correlation for the
peptides shown in Figure 2c was 0.49, which is significant at the 2% level, and the corresponding linear regression
of ∆pEC50 on Λ was significant at the 1% level. These results demonstrate that CPL-driven database searching can
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accurately identify peptide sequences recognized by individual TCRs.
CPL-driven database searching can identify viral ligands that initiate CD8+ T-cell responses
We next assessed whether our approach could be used to identify the original viral ligand that drove the initial expan-
sion of a given clonotype, independently of prior knowledge of this ligand or the identity of the infectious agent. For
this purpose, we constructed a database containing all human viral pathogens as well as all zoonotic viruses capable
of or suspected to be capable of infecting humans, to the best of our knowledge and judgement. Each of the 1,872,417
unique nonamer peptide sequences in this database of 10,733 distinct viral proteins was assigned a Λ-value according
to eqn (8), with parameter values derived from a nonameric CPL-scan of clone E7NLV. These sequences were ranked
by Λ, which represents the likelihood of recognition by this clone. The index peptide of E7NLV, NLVPMVATV, was
found to be the top-ranked sequence, suggesting that CPL-driven database searching alone can suffice to identify
the infectious agent (Figure 3 and Table S1A). We examined the functional response to a further nine top-ranking
peptides. In addition to the index, which had been recovered without prior knowledge, five out of the further nine
predicted peptides were capable of activating E7NLV, with three being strong agonists (Figure 3). Thus, CPL-driven
database searching could select from a comprehensive database the pathogen-derived sequence that had driven the
initial expansion of clone E7NLV, as well as crossreactive peptide ligands.
CPL-driven database searching can identify viral ligands recognized by EBV-specific CD8+ T-cells
To extend the foregoing findings to other specificities, we examined a panel of Epstein-Barr virus (EBV)-specific
CD8+ T-cell clones. EBV has been implicated in the pathogenesis of autoimmune diseases such as multiple sclero-
sis27. Our knowledge regarding the role of this virus in such diseases would therefore be advanced by a method that
can define antigen specificity within the associated CD8+ T-cell clonal expansions28. We initially focused on clones
SB16 and SB12, which are both specific for the immunodominant HLA A*0201-restricted BMFL1280−288 epitope
GLCTLVAML (Table 1).
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A nonamer CPL scan of the SB16 clone revealed multiple hits across the peptide backbone with dominant re-
sponses at each position (Figures 4 and S1). The raw CPL scan data set was used to conduct a CPL-driven search
of the human viral database. Table S1B lists the nonameric peptide sequences ranked as the twenty sequences most
likely to be recognized out of a database of 1,872,417 different nonameric sequences. The index peptide sequence
for this clone was found to have the largest Λ-value, consistent with the result obtained for E7NLV (Table S1A). We
next performed a nonamer CPL scan with clone SB12 (Table 1). In contrast to the result obtained with SB16, we did
not detect responses that rose substantially above background, except at position 8, where a response to methionine
(M) was observed (Figure S2); these results were too scanty to permit a meaningful CPL-driven database search and
suggest that SB12 is highly ligand-specific, recognizing only a small number of peptides. This characteristic may be
shared with other anti-viral CD8+ T-cells, as we observed a similar result with ALF3, a CD8+ T-cell clone specific for
the immunodominant HLA A*0201-restricted influenza A M158−66 epitope GILGFVFTL (Table 1 and Figure S3).
CD8+ T-cells specific for longer epitopes play a major role in the response against EBV.29 We therefore exam-
ined two well-characterized clones with different EBV-derived peptide length preferences. Clone SB14 is specific
for the immunodominant HLA B*3508-restricted EBNA1407−417 epitope HPVGEADYFEY (Table 1) and we therefore
performed an 11-mer CPL scan on this clone (Figures 4 and S4). A CPL-driven search of the human viral database pre-
dicted that the two most likely recognized 11-mer peptide sequences were HPVAEADYFEY and HPVGDADYFEY (4A
and 5D variants of the index peptide), with the index peptide itself ranking third in the list (Table S1C). Clone SB27
is specific for the HLA B*3508-restricted BZFL152−64 epitope LPEPLPQGQLTAY and exhibits a strong preference
for 13-mer peptides.25 A 13-mer CPL scan of this clone revealed a high degree of crossreactivity (Ekeruche-Makinde
et al.25, and Figure 4), but notwithstanding this apparent promiscuity, the index peptide still ranked twelfth in a
CPL-driven search of the human viral database (Table S1D).
Collectively, these findings demonstrate that viral peptide specificities can be identified efficiently by means of
peptide length-matched CPL-driven database searching. In general, anti-viral CD8+ T-cells appear to be highly
focused on their index peptide sequence, notwithstanding an inherent degree of crossreactivity.
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CPL-driven database searching can identify variants recognized by HIV-1-specific CD8+ T-cells
To examine the utility of CPL-driven database searching in other viral infections, we studied two previously de-
scribed TCRs specific for the immunodominant human immunodeficiency virus type 1 (HIV-1)-derived HLA A*0201-
restricted p17 Gag77−85 epitope SLYNTVATL (Table 1). Consistent with the results above, a CPL-driven search of
the human viral database using nonamer CPL scan data from the 003 clone identified the index sequence as the most
likely agonist (Figures 4 and S5; Table S1E). Moreover, a number of epitope variants were predicted, many of which
have been verified at the functional level.30,31 Similar results were obtained with the 868 TCR, in this case scanning
primary CD8+ T-cells transduced with the corresponding lentiviral construct (Figures 4 and S6; Table S1F). CPL-
driven database searching can therefore predict epitope variant crossreactivity patterns, which may prove useful in the
assessment of CD8+ T-cell responses against highly variable viruses.
Extending the approach to the identification of self ligands targeted by CD8+ T-cells
In addition to the identification of virus-derived epitopes, it would be advantageous if CPL-driven database searching
could reveal self-derived peptide targets, as this would provide a means to identify the antigenic proteins involved in
autoimmune disease and, moreover, to discover novel cancer epitopes recognized by CD8+ T-cells. To this end, we
created a human protein database as described below. The CD8+ T-cell clones ILA1 and MEL5 were chosen because
they are both specific for epitopes derived from self proteins. In particular, ILA1 is specific for the HLA A*0201-
restricted human telomerase reverse transcriptase (hTERT)540−548 sequence ILAKFLHWL (Table 1). A nonamer CPL
scan previously carried out for ILA125,32 was used to conduct a CPL-driven search of the human protein database
(Figure 4). The index peptide was ranked by Λ as the eighth most likely nonameric peptide sequence to be recognized
by the ILA1 TCR, suggesting that this approach is capable of identifying self-derived ligands targeted by TCRs (Table
S2A).
However, a previous study indicated that ILAKFLHWL is not expressed at the cell surface33, and therefore ILA1
may not be typical of a self-reactive TCR that has survived negative selection. To address this potential confounder, we
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studied MEL5, which recognizes the HLA A*0201-restricted Melan-A/MART1 epitope EAAGIGILTV.34 A nonamer
CPL scan, which had previously been carried out for MEL5,25,34 was used to conduct a CPL-driven search of the
human protein database (Figure 4). The EAAGIGILTV peptide sequence did not appear in the top twenty peptides
predicted to activate MEL5 (EAAGIGILTV ranked 55th; Table S2B). Self-reactive TCRs are possibly not focused on
their index peptide sequence to the same degree as virus-specific TCRs and, consequently, the CPL-driven database
searching approach may fail to identify disease-relevant ligands targeted by self-reactive TCRs. The use of smaller
disease-specific or organ-specific databases might improve the applicability of our strategy in this context.
Overview of CPL-driven database screening and development of a webtool
Every TCR is characterized by a unique peptide recognition signature, which comprises three different components:
(i) a peptide length preference; (ii) the number of peptides recognized at this preferred length; and (iii) the sequence
identity of these peptide agonists, which may be either pathogen-derived or self-derived.20,25 Figure 5 provides an
overview of a three-stage strategy to dissect the peptide recognition signature of a given TCR. In the first stage,
peptide length preference is determined by examining functional recognition of a “sizing scan” comprising random
peptide libraries of different lengths (x8, x9, x10, x11, x12, x13, where x denotes any of the 19 L-amino acids excluding
cysteine).25 In the second stage, CPL-biased sampling19 is used to quantify the number of recognized peptides. In the
third stage, which is the novel step introduced in the present study, CPL-driven database searching is used to identify
antigen specificity. To augment community-wide access to CPL-driven database searching, we created a dedicated
webtool as part of the WSBC webtools framework.
Discussion
Although CD8+ T-cells protect the human body from countless intracellular pathogens and malignant processes,
they are also heavily implicated in the etiology of life-threatening and incurable immune-mediated diseases. It is
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conceivable that non-self antigens elicit CD8+ T-cell responses that are initially target-appropriate but subsequently
become pathogenic as a consequence of crossreactivity with self epitopes. In this study, we developed and validated
a technique termed “CPL-driven database searching”, which allows for the reliable identification of cognate viral
epitopes recognized by CD8+ T-cells with as yet unknown specificities. Initially, we constructed a viral database
containing human and zoonotic viruses (with an established or potential ability to infect humans). This database was
curated to include non-redundant and reviewed sequences only and contained a total of 10,733 viral proteins. We then
selected a panel of herpesvirus-specific CD8+ T-cell clones spanning two different restriction elements (HLA A*0201
and HLA B*3508) and a range of epitope lengths (9–13 amino acids). As CD8+ T-cells typically display an explicit
preference for peptide length,25 we focused our attention on peptide length-matched CPL scans to determine the amino
acid preferences of each clone at each peptide position. The majority of clones in our panel elicited strong responses
with distinct preference hierarchies at each position of the peptide. CPL scan datasets were used to assign an agonist
likelihood score (Λ) to each peptide of preferred length in the entire human viral database, thereby producing a list
of potential peptide ligands in order of likelihood of recognition. For all herpesvirus-specific clones tested, the index
epitope ranked in the top-twenty most likely recognized peptide sequences from the entire human viral database, even
for the highly crossreactive CD8+ T-cell clone SB27, which is specific for an HLA B*3508-restricted 13-mer EBV-
derived epitope. These findings indicate that anti-viral CD8+ T-cells display high levels of functional sensitivity for
the index epitope, consistent with an efficient in vivo selection process based on interclonal competition for antigen.35
It is noteworthy that one EBV-specific CD8+ T-cell clone tested failed to respond to any CPL scan mixtures
except mixture M@8 and was not suitable for further analysis. This difficulty could be emblematic of a small subset
of CD8+ T-cell clones that are highly focused on the salient ligand and therefore fail to respond to a sufficiently large
number of peptides within the CPL mixtures. CPL-driven database searching is not applicable to such TCRs, which
behave as “non-responders” in the context of a CPL scan. Moreover, to ensure the accuracy of CPL-driven database
searching, experimental CD8+ T-cell populations must be monoclonal and must be subjected to multiple replicates of
each scan.
The viral pathogen and human proteome databases were collated and curated with a view to making them as
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exhaustive as possible. It may be considered that the relatively small size of the former database contributes to the
success of our method, but this is not the case. Indeed, when the two databases were merged, comparable rankings
were obtained. In terms of relative rank, the merged database was slightly better for most TCRs, indicating that
the ranks derived from the viral database are actually more conservative. Notwithstanding these advantages, the
identification of relevant epitopes in the human proteome database is much more challenging, likely due to the fact
that even physiologically relevant autoimmune epitopes are typically recognized at low levels of functional sensitivity.
Work is in progress to build and test similar databases for bacterial and fungal pathogens. These will be added to the
webtool on completion.
It is known that HIV-1 can escape from the CD8+ T-cell response via single point mutations in key epitopes.36 If
CD8+ T-cells are inherently crossreactive, why does the HIV-1-specific CD8+ T-cell response exhibit such exquisite
specificity? Our findings point to a possible explanation. The HIV-1-specific TCRs examined in this study (003
and 868) were strongly focused on their index peptide sequence, increasing the probability that epitope mutation
will result in loss of recognition. In contrast, CD8+ T-cells with a more crossreactive phenotype are associated with
delayed disease progression.37,38 It is therefore feasible that CPL-driven database searching will provide a useful tool
to delineate the requirements for effective CD8+ T-cell-mediated immunity against HIV-1.
CPL-driven database searching may also assist in the identification of self-derived epitopes, such as those targeted
by autoimmune or cancer-specific CD8+ T-cells. Indeed, similar approaches to ligand hunting in these settings have
been described previously.39,40 Although we successfully identified the index peptide for the ILA1 clone, it has been
shown that the cognate epitope is not expressed on the surface of HLA A*0201+ hTERT+ cancer cell lines,33 which
renders it less likely that this epitope is expressed in the thymus. If so, ILA1 will not have been subjected to negative
selection in the thymus, which could account for the highly focused phenotype of this clone. In contrast, the index
EAAGIGILTV peptide recognized by the MEL5 clone was ranked at position 55. It may therefore be more challenging
to identify bona fide self-derived epitopes that are expressed in the thymus. Generation of disease-specific or organ-
specific protein databases might circumvent this problem by narrowing the search for relevant epitopes, but further
work is required to test such focused screening strategies.
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In summary, we have developed and validated an approach that can be used to dissect the peptide recognition
signature of any given TCR. Accordingly, we therefore anticipate that CPL-driven database searching will find clinical
utility across a range of diseases.
Methods
Cells
Ten human CD8+ T-cell clones spanning eight different specificities were used in this study (Table 1). The index pep-
tides for the following CD8+ T-cell clones are derived from viral proteins; E7NLV, SB16, SB12, ALF3,41 SB14,42
SB27,43 00344 and 868.44 The index peptides for the remaining two CD8+ T-cell clones, ILA145 and MEL5,46 are
derived from human self proteins. Clone E7NLV is specific for the HLA A*0201-restricted HCMV-derived pp65
epitope NLVPMVATV (residues 495–503). Four clones are specific for epitopes derived from EBV proteins: SB16
and SB12, which both recognize the HLA A*0201-restricted BMLF1 epitope GLCTLVAML (residues 280–288);
SB14, which recognizes the HLA B*3508-restricted EBNA1 epitope HPVGEADYFEY (residues 407–417); and SB27,
which recognizes the HLA B*3508-restricted BZLF1 epitope LPEPLPQGQLTAY (residues 52–64). Clone ALF3
is specific for the HLA A*0201-restricted influenza A-derived M1 epitope GILGFVFTL (residues 58–66; Clement
et al.41). The 003 and 868 TCRs are both specific for the HLA A*0201-restricted HIV-1-derived p17 Gag epi-
tope SLYNTVATL (residues 77–85). Clone ILA1 is specific for the HLA A*0201-restricted hTERT-derived se-
quence ILAKFLHWL (residues 540–548), and clone MEL5 is specific for the Melan-A-derived heteroclitic sequence
ELAGIGILTV (residues 26–35). All CD8+ T-cells were maintained in RPMI 1640 containing 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine and 10% heat-inactivated fetal calf serum (all Life Technologies), supple-
mented with 2.5% Cellkines (Helvetica Healthcare), 200 IU/ml interleukin IL-2 and 25 ng/ml IL-15 (both PeproTech).
C1R-HLA A*0201 and T2-HLA B*3508 target cells were generated and maintained as described previously.47
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Combinatorial peptide library scans
CPL libraries were synthesized in a positional scanning format (Pepscan PrestoLtd). All CPL scans were performed
as previously described.19,25,32 Briefly, 6×104 target cells were incubated with various library mixtures (at 100 µM)
in duplicate for 2 hours at 37◦C. After peptide pulsing, 3×104 clonal CD8+ T-cells were added and the plates were
incubated overnight to 37◦C. Supernatants were then collected and assayed for MIP1β content by ELISA (R&D
Systems).
Functional sensitivity assays
For MIP1β ELISA assays, 6× 104 target cells were pulsed with peptide at the indicated concentrations for 2 hours
at 37◦C. Subsequently, 3× 104 clonal CD8+ T-cells were added and the plates were incubated overnight at 37◦C.
Supernatants were then collected and assayed for MIP1β by ELISA (R&D Systems). For lysis assays, target cells
were loaded with 51Cr for 1 hour and then plated at 5,000 cells per well in 75 µl medium. Clonal CD8+ T-cells were
added to a total volume of 150 µl. Target cells alone were to used to measure spontaneous release and Triton 100
was used to measure total release. After incubation for 4 hours at 37◦C, 15 µl supernatant per well was harvested and
mixed with 150 µl OptiPhaseSupermix Scintillation Cocktail (Perkin-Elmer). Release of 51Cr was measured with a
Microbeta Counter (Wallac) and the resulting data were used to calculate % specific lysis according to the formula:
Experimental release− spontaneous release
Total release− spontaneous release ×100%
Functional sensitivity was determined as described previously;19 it is expressed as pEC50, the cologarithm to base 10
of the 50%-efficacy concentration as determined from dose-response experiments in which antigen-presenting cells
were incubated with agonist across a series of dilutions.
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Derivation of the agonist likelihood score method
The functional sensitivity of a clone of interest to a given peptide ligand depends on several factors, a key parameter
being the rate at which a single peptide-MHC copy elicits TCR triggering.48,49 We quantify TCR degeneracy as the
probability that the functional sensitivity of a given TCR to a randomly chosen ligand exceeds a given value ω;50
this probability expresses the degeneracy at ω . Let wi j denote the functional sensitivity of TCR i to peptide j,
where wi j ≤ ŵ for all i and j (with ŵ > 0). Besides being a function of clonotype i and peptide-MHCI species j,
functional sensitivity depends on additional factors such as phenotypic differentiation stage and coreceptor expression;
we assume such additional parameters to be uniform across the experiments performed in the present study. If n
is the length of the peptides considered, then 20n is the size of the peptide universe (the total number of distinct
peptides). Given a peptide subsetS of the peptide universe, the general question of epitope prediction can be framed
as follows: for a clone of interest i, determine the quantity P[wi j >ω| j ∈S ], i.e. the probability that wi j exceeds a set
value ω ∈ [0, ŵ], when it is known that the peptide ligand j belongs to this setS . For a peptide j selected at random,
we have P[ j ∈S ] = 20−n|S |, where |S | denotes the cardinality ofS . Then, by Bayes’ Rule,
P[wi j > ω| j ∈S ] = P[ j ∈S |wi j > ω]P[wi j > ω]P[ j ∈S ] = P[ j ∈S |wi j > ω] P[wi j > ω]20
n|S |−1 , (1)
which expresses the problem in the empirically more accessible probability P[ j ∈S |wi j > ω], i.e. the chance that a
randomly selected peptide j belongs toS , given that the functional sensitivity wi j to this peptide is at least ω . A direct
estimate of this probability could be obtained by subjecting randomly generated peptides to a functional sensitivity
assay and verifying whether they also belong to S . However, this would be highly inefficient and would require
millions of random peptides to be reasonably accurate, as the vast majority would be practically “null” (i.e. having
pEC50 well below the detection limit). More progress can be made provided that S is a cylinder, which is a special
type of set, defined as follows: let 1 ≤ p1 < p2 < ... < pk ≤ n represent a choice of positions in the peptide and let
α1,α2, ...,αk be a choice of amino acid residues for these positions (several or all of these αs could be the same amino
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acid). Then a peptide set of the form
C p1,...,pkα1,...,αk = { peptides such that the residue at position pr is αr for r = 1, ...,k}
is called a cylinder of rank k. For example, the rank-2 cylinder C 4,5Q,R contains all and only the peptides with glutamine
at position 4 and arginine at position 5. The cardinality of a rank-k cylinder is 20n−k; in particular, the rank-0 cylinder
is the entire peptide universe, as no amino acids are specified at any position, whereas a rank-n cylinder contains just
one peptide, all positions having been specified.
Given a rank-k cylinder C p1,...,pkα1,...,αk , let J denote a subset of {p1, . . . , pk}, and let C Jα[J] be the lower-order cylinder
which has amino acids specified only at the positions in J, agreeing with the ‘parent’ C p1,...,pkα1,...,αk at those positions, that
is, C Jα[J] is formed by dropping from C
p1,...,pk
α1,...,αk the positions not present in J. Let ` be an integer 0 ≤ ` ≤ k, and let({p1,...,pk}
`
)
denote the set of all subsets J of size `, so that cylinders can be decomposed as follows:
C p1,...,pkα1,...,αk =
⋃
J∈({p1 ,...,pk}k−1 )
C Jα[J]. (2)
Next, let correlation functions be defined recursively, as follows:
K p1,...,pkα1,...,αk(ω; i) =
20k P[ j ∈ C p1,...,pkα1,...,αk | wi j > ω]
∏k−1`=0∏J∈({p1 ,...,pk}` )
KJα[J](ω; i)
(3)
with lowest-order boundary condition K /0/0 (ω, i) ≡ 1 for all ω ∈ [0, ŵ]. The correlation functions permit an exact
solution of the epitope prediction problem, since eqn (3) implies that
P[ j ∈ C p1,...,pkα1,...,αk | wi j > ω] = 20−k
k
∏`
=1
∏
J∈({p1 ,...,pk}` )
KJα[J](ω; i) (4)
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and with eqn (1) this can be transformed into the probability that a peptide is an agonist with functional sensitivity of
at least ω , given that the peptide belongs to some cylinder of interest, which might be of appropriate cardinality, be
this almost the entire peptide universe or a singleton set (i.e. a rank-n cylinder containing only that peptide).
The crucial step is to establish a connection to CPL data. Consider the CPL mixture K@3, in which lysine is
fixed at position 3 with all other positions random. This mixture corresponds to the rank-1 cylinder C 3K. Similar
correspondences obtain for all 180 CPL mixtures (in the case n = 9). Suppose that a peptide contributes appreciably
to the CPL read-out whenever wi j exceeds a certain cut-off value ω˜ , let Yαp (i) denote the read-out signal obtained when
exposing clone i to the mixture α@p, and let A denote the set of 20 amino acids. We then propose the following
identification:
P[ j ∈ C pα | wi j > ω˜] =
Yαp (i)
∑α ′∈A Yα
′
p (i)
(5)
where p is the single specified position (with 1 ≤ p ≤ n) and α is the specified amino acid residue at this position.
The rank-1 specialisation of eqn (3) is as follows:
P[ j ∈ C pα | wi j > ω] = 120K
p
α(ω; i) (6)
and thus, with ω set to ω˜ , eqn (5) provides a way to estimate the lowest-order correlation function from the CPL
scan data. The proposed identification, eqn (5), rests on somewhat idealised assumptions, since peptides with values
with wi j below ω˜ may still contribute if they are presented at high copy numbers on the antigen-presenting cell and
conversely, peptides with high wi j may fail to contribute substantially.
In principle, higher-rank correlation functions can be estimated from higher-rank CPLs, which contain library mix-
tures corresponding to higher-rank cylinders (e.g. the mixture K@3&A@5 corresponds to the rank-2 cylinder C 3,5K,A),
but the number of peptide mixtures required, and hence the cost of the experiment, quickly becomes prohibitive.
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Rank-1 correlations can nevertheless be informative as long as that higher-order correlations do not dominate. Math-
ematically speaking, the higher-order correlations are neglected by setting the corresponding K-values equal to 1; this
amounts to a truncation of the exact expansion in eqn (4). Combining eqns (1) and (5) with the truncated version of
eqn (4), we obtain the following for a specified peptide α1α2 · · ·αn:
lnP[wi j > ω˜ | peptide j is α1α2 · · ·αn]≈ lnPi(ω˜)+n ln{20}+
n
∑
p=1
ln
Yαpp (i)
∑α ′∈A Yα
′
p (i)
(7)
where Pi(ω˜) is the unconditional probability that the functional sensitivity of clone i for a peptide selected at random
exceeds ω˜ . For the purpose of ranking peptides, we can proceed without knowing the value of Pi(ω˜), since it merely
represents a fixed offset term, once a clone has been fixed. We therefore retain only the last term in eqn (7), which we
call the agonist likelihood score:
Λ(α1α2 · · ·αn; i) =
n
∑
p=1
ln
Yαpp (i)
∑α ′∈A Yα
′
p (i)
. (8)
MATLAB scripts were written to scan the human and viral pathogen databases and to evaluate Λ for all potential
peptides of the clone-appropriate length in the proteomes, i.e. all subsequences of the specified length irrespective
of antigen processing constraints. Excluded were those containing one or more unspecified residues, appearing as X
in the databases; such cases were rare. NetChop predictions of MHCI binding were also obtained via the publicly
available online tool, but these data are not reported here because we did not find that they winnowed the candidate
peptide list.
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Data access provisions
Databases
Human and viral databases were compiled on the basis of publicly available protein sequence databases provided
by NCBI (National Center for Biotechnology Information), UniProt (Universal Protein Resource), and PDB (Protein
Data Bank). The human proteome database was assembled using protein sequence information taken from the fol-
lowing data sources:
(i) file protein.fa.gz from
ftp://ftp.ncbi.nih.gov/genomes/Homo sapiens/protein/;
(ii) file human.protein.faa.gz from
ftp://ftp.ncbi.nih.gov/refseq/H sapiens/mRNA Prot/;
(iii) http://www.uniprot.org/uniprot/ for canonical and isoform sequence data in FASTA format (Protein Knowl-
edgebase search terms: organism:homo sapiens and reviewed:yes);
(iv) http://www.pdb.org/pdb/home/home.do for human protein sequences
(search terms: taxonomy:homo sapiens, polymer type:protein, custom tabular report:sequence, macromolecular name, source).
The viral protein database was assembled using protein sequence information taken from the following data sources:
(i) file viral.1.protein.faa.gz from
ftp://ftp.ncbi.nih.gov/refseq/release/viral/;
(ii) file all.faa.tar.gz from
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ftp://ftp.ncbi.nih.gov/genomes/Viruses;
(iii) http://www.uniprot.org/uniprot/ for canonical and isoform sequence data in FASTA format (Protein Knowl-
edgebase search terms: host:human and reviewed:yes);
(iv) http://www.pdb.org/pdb/home/home.do for viral protein sequences
(search terms: taxonomy:viruses, polymer type:protein, custom tabular report:sequence, macromolecular name, source).
(Remote file names and locations may be subject to change.) The assembled databases were curated to contain non-
redundant and certified sequences, comprising 54,886 human and 187,840 viral proteins, respectively. As the viral
database was compiled from a variety of data sources, care was taken to ensure that each pathogen was identified by
a unique key and that different keys for the same pathogen used in different sources were slaved to the master key.
A list of approximately 250 viral species with known or potential ability to infect humans was compiled and used to
restrict the viral database to pathogens that infect humans; avoidance of ambiguity poses a major challenge in the face
of issues surrounding the distinction of closely related species of viral pathogens and the frequent use of alternative
designations. Ultimately, there were 10,733 non-redundant protein sequences in the database of proteomes of viral
pathogens that pose a potential danger to human beings.
Webtool
A novel webtool, PI CPL, was written in MATLAB and compiled using the MATLAB Compiler. The binary code
was integrated into the WSBC webtools framework, accessible at
http://wsbc.warwick.ac.uk/wsbcToolsWebpage.
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The framework provides a browser-based user interface, from which jobs are launched and run on a multicore compu-
tational cluster. Feedback on progress is provided via a webpage if required. Results are presented as a webpage and
can also be downloaded for offline viewing. In the case of PI CPL, these consist of a text file containing a list of the
top-scoring peptides, which is designed to be viewed as a spreadsheet, plus a heat map image. A database of results
is maintained as a job history for logged-on users. To request an account, please email the corresponding author.
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Figure legends
Figure 1 Nonamer CPL scan of E7NLV:
6×104 C1R-A?0201 target cells were pulsed in duplicate with mixtures from a 9-mer CPL scan (100 µM) at 37◦C.
After 2 hours, 3×104 E7NLV CD8+ T-cells were added and incubated overnight. The supernatant was then harvested
and assayed for MIP1β by ELISA.
Figure 2 Recognition of 30 randomly chosen and uniformly distributed peptides by the E7NLV clone:
(a) 1×103 C1R-A?0201 target cells were pulsed with a panel of 30 peptides over a range of concentrations in
duplicate for 1 hour at 37◦C. 2×103 E7NLV CD8+ T-cells were subsequently added at an E:T ratio of 2:1. Cytotoxic
activity was measured via chromium release from target cells expressing C1R-A?0201 target cells as described in the
Methods. (b) Relative functional sensitivity (∆pEC50) for the same 30 peptides compared to index (∆pEC50 = 0).
(c) Scatter plot of ∆pEC50 versus Λ for the same 30 peptides.
Figure 3 E7NLV recognition of the top six peptides (a) and peptides ranked 7-10 (b) from the human pathogen
database: In (b), peptide recognition is compared to index (black upside-down triangle). Cytotoxic activity was
measured via chromium release from target cells expressing HLA A?0201 as described in the Methods.
Figure 4 Heat maps summarizing CPL scan data for: E7NLV (a), SB16 (b), SB14 (c), SB27 (d), 003 (e), 868
(f), ILA1 (g) and MEL5 (h). CPL scan data are normalized in each row so that the values range from high (red) to
low (blue); the maximum intensity is the largest of all red values in the rows. Amino acids are grouped according to
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their physicochemical properties, as follows: polar, uncharged amines: Q, N; polar, uncharged alcohols: T, S; small:
G, A, C; hydrophobic: A–H; aliphatic: V, I, L; aromatic: Y, F, W, H; large: F, W; charged basic: H, K, R; and charged
acidic: E, D.
Figure 5 Three-stage strategy to dissect the peptide recognition signature of individual TCRs:
To augment community-wide access to CPL-driven database searching, we have created a dedicated webtool as part
of the WSBC webtools framework.
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Table for main text
Clone Specificity HLA Minimal Epitope Peptide Reference
ID Restriction Length
E7NLV HCMV A*0201 NLVPMVATV 9 *
SB16 EBV A*0201 GLCTLVAML 9 *
SB12 EBV A*0201 GLCTLVAML 9 *
ALF3 Influenza A A*0201 GILGFVFTL 9 41
SB14 EBV B*3508 HPVGEADYFEY 11 42
SBS27 EBV B*3508 LPEPLPQGQLTAY 13 43
003 HIV-1 A*0201 SLYNTVATL 9 44
868 HIV-1 A*0201 SLYNTVATL 9 44
ILA1 Telomerase A*0201 ILAKFLHWL 9 45
MEL5 Melan-A A*0201 ELAGIGILTV 10 46
Table 1: CD8+ T-cell clones used in this study.
* First description of this CD8+ T-cell clone. The parental clone was used in all cases except for 868, where primary
CD8+ T-cells were transduced to express the 868 TCR.
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Identifying natural CD8+ T-cell agonists 
SUPPLEMENTAL FIGURE LEGENDS 
Figure S1: CPL scan of SB16 CD8+ T-cells: 6x104 target cells expressing HLA A*0201 
were pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37ºC. After 2 
hours, 3x104 SB16 CD8+ T-cells were added and incubated overnight. The supernatant was 
then harvested and assayed for MIP1β by ELISA.  
Figure S2: CPL scan of SB12 CD8+ T-cells: 6x104 target cells expressing HLA A*0201 
were pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37ºC. After 2 
hours, 3x104 SB12 CD8+ T-cells were added and incubated overnight. The supernatant was 
then harvested and assayed for MIP1β by ELISA.  
Figure S3: CPL scan of ALF3 CD8+ T-cells: 6x104 target cells expressing HLA A*0201 
were pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37ºC. After 2 
hours, 3x104 ALF3 CD8+ T-cells were added and incubated overnight. The supernatant was 
then harvested and assayed for MIP1β by ELISA.  
Figure S4: CPL scan of SB14 CD8+ T-cells: 6x104 target cells expressing HLA B*3508 
were pulsed in duplicate with mixtures from an 11-mer CPL scan (100 μM) at 37ºC. After 2 
hours, 3x104 SB14 CD8+ T-cells were added and incubated overnight. The supernatant was 
then harvested and assayed for MIP1β by ELISA.  
Figure S5: CPL scan of 003 CD8+ T-cells: 6x104 target cells expressing HLA A*0201 were 
pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37ºC. After 2 hours, 
3x104 003 CD8+ T-cells were added and incubated overnight. The supernatant was then 
harvested and assayed for MIP1β by ELISA.  
Figure S6: CPL scan of 868 CD8+ T-cells: 6x104 target cells expressing HLA A*0201 were 
pulsed in duplicate with mixtures from a 9-mer CPL scan (100 μM) at 37ºC. After 2 hours, 
3x104 CD8+ T-cells transduced with the 868 TCR were added and incubated overnight. The 
supernatant was then harvested and assayed for MIP1β by ELISA.  
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Supplementary Materials: Supplemental Tables
Rank Λ Peptide Viral ID
Sequence
1 -13.21 NLVPMVATV HUMAN CYTOMEGALOVIRUS
2 -14.0927 IVLGLIATA EASTERN EQUINE ENCEPHALITIS
3 -14.6606 NGVRVLATA HUMAN METAPNEUMOVIRUS
4 -15.5807 HVLGCLITV DENGUE VIRUS 2
5 -15.9006 LGMCCIITA DENGUE VIRUS 2
6 -15.9495 MGVCMIAHV HUMAN HERPESVIRUS 2
7 -15.9934 MINPLVITT GUANARITO VIRUS
8 -16.0104 ITNCLLSTA CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS
9 -16.1097 KDLVLLATI HUMAN ADENOVIRUS B/D/E
10 -16.2304 NIVCPLCTL HUMAN PAPILLOMAVIRUS 1A
11 -16.2601 MILGPISTA MIDDELBURG VIRUS
12 -16.3254 IIVGCVPTI HUMAN PAPILLOMAVIRUS 179
13 -16.52006 RLTGLLATS HUMAN HERPESVIRUS 1
14 -16.5221 ILLACLATL ALKHUMRA HEMORRHAGIC FEVER VIRUS
15 -16.5859 VVNPVVATA HUMAN CYTOMEGLAOVIRUS
16 -16.5929 CMLRLVCTA MOLLUSCUM CONTAGIOSUM VIRUS
17 -16.7047 KTNPLPATP HUMAN HERPESVIRUS 1
18 -16.735 IVLRMVIYV HUMAN IMMUNODEFICIENCY VIRUS 2
19 -16.779 MMLVPLITV MONKEYPOX VIRUS
20 -16.8048 FILGIIITV VARIOLA VIRUS
Table S1A: CPL-driven search of the human viral database for E7NLV (“Index” peptide sequence in boldface).
Rank Λ Peptide Viral ID
Sequence
1 -15.3323 GLCTLVAML HUMAN HERPESVIRUS 4
2 -15.803 KMNTLVAQS HUMAN TMEV-LIKE CARDIOVIRUS
3 -16.2656 SLNTLQPML HUMAN PARAINFLUENZAVIRUS 1/3
4 -16.7366 LLEYLYMMR TANAPOX VIRUS
5 -16.7367 GQNLLYANS HUMAN ADENOVIRUS B/C
6 -16.7949 SLNLPVAKL HUMAN IMMUNODEFICIENCY VIRUS 2
7 -16.8288 ILNTLVAYQ HUMAN HERPESVIRUS 7
8 -16.9413 SLGLLVAWA CERCOPITHECINE HERPESVIRUS 1
9 -17.0839 LLDTLVMQL HUMAN HERPESVIRUS 8
10 -17.1431 LLELYVPKS HUMAN HERPESVIRUS 7
11 -17.2793 TINTLIAMK TANAPOX VIRUS
12 -17.3584 LYNLLVLWL HUMAN HERPESVIRUS 6A
13 -17.3613 TLDTLVAMK MOLLUSCUM CONTAGIOSUM VIRUS
14 -17.4863 ILWLLVMIF HUMAN CORONAVIRUS Nl63
15 -17.5593 LQELLIQQW SARS CORONAVIRUS
16 -17.5627 ILNLLVIQR ISFAHAN VIRUS,
CHANDIPURA VIRUS,
VESICULAR STOMATITIS INDIANA VIRUS
17 -17.5649 NAELLVAME INFLUENZA A VIRUS
18 -17.5647 SLNLPVAKV HUMAN IMMUNODEFICIENCY VIRUS 1
19 -17.5699 TMDTLIAMK MONKEYPOX VIRUS
20 -17.6729 TQELLYAYT DHORI VIRUS
Table S1B: CPL-driven search of the human viral database for SB16 (“Index” peptide sequence in boldface).
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Rank Λ Peptide Viral ID
Sequence
1 -17.2068 HPVAEADYFEY HUMAN HERPESVIRUS 4
2 -17.3948 HPVGDADYFEY HUMAN HERPESVIRUS 4
3 -18.1085 HPVGEADYFEY HUMAN HERPESVIRUS 4
4 -20.203 SPQWAADYAFL CERCOPITHECINE HERPESVIRUS 1
5 -20.3323 SPRWAADYAFL CERCOPITHECINE HERPESVIRUS 16
6 -21.2014 FVNFNVDWVFF HUMAN CORONAVIRUS NL63
7 -22.0733 LASLGVDYSEF SUID HERPESVIRUS 1
8 -22.5825 TPNYDIDLAFF HUMAN ADENOVIRUS B/E
9 -22.6401 YPNWDTIYYED HUMAN PAPILLOMAVIRUS 167
10 -22.7321 LHAVPIDYFFL ADULT DIARRHEAL ROTAVIRUS
11 -23.0102 PCMVGPDYAYF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
12 -23.0682 KNVWDVDYSAF FOOT-AND-MOUTH DISEASE VIRUS
13 -23.1986 RNVWDVDYSAF FOOT-AND-MOUTH DISEASE VIRUS
14 -23.3088 TGCCSTDYFEM HUMAN CORONAVIRUS 229E
15 -23.5894 EVLREADYSED ASTROVIRUS VA1
16 -23.5944 CLLLSTDWVEF SAIMIRIINE HERPESVIRUS 2
17 -23.6211 DAIVEADYSAN TIOMAN VIRUS
18 -23.7977 SVAPEVDWVAF HUMAN CORONAVIRUS NL63
19 -23.9037 DAVVEADYSAN MENANGLE VIRUS
20 -23.9122 PTSVPLDWAAF HUMAN HERPESVIRUS 2
Table S1C: CPL-driven search of the human viral database for SB14 (“Index” peptide sequence in boldface).
Rank Λ Peptide Viral ID
Sequence
1 -34.9645 NVASLUGSTVREY MOLLUSCUM CONTAGIOSUM VIRUS
2 -35.3404 LIENVASLUGSTV MOLLUSCUM CONTAGIOSUM VIRUS
3 -35.6833 VASLUGSTVREYT MOLLUSCUM CONTAGIOSUM VIRUS
4 -35.8699 SLUGSTVREYTQM MOLLUSCUM CONTAGIOSUM VIRUS
5 -35.9034 ASLUGSTVREYTQ MOLLUSCUM CONTAGIOSUM VIRUS
6 -36.0576 LLIENVASLUGST MOLLUSCUM CONTAGIOSUM VIRUS
7 -36.481 VLLIENVASLUGS MOLLUSCUM CONTAGIOSUM VIRUS
8 -36.6355 YLAPAPQTPLAFY HUMAN HERPESVIRUS 2
9 -36.6396 APLPCFQNNCLFL ENCEPHALOMYOCARDITIS VIRUS
10 -36.6518 SAAPAFQAPRFGL WHATAROA VIRUS
11 -36.6783 HPFGSPQTDNPCY TORQUE TENO VIRUS 19
12 -36.7192 LPEPLPQGQLTAY HUMAN HERPESVIRUS 4
13 -36.7205 SAVKSPQAPLVLC JUNIN ARENAVIRUS
14 -36.7216 LALPAPPSQPFPW HUMAN T-LYMPHOTROPIC VIRUS 2
15 -36.7294 SAIKSPQAPLVLC JUNIN VIRUS
16 -36.7331 WPEPTFPSRWYWL HUMAN HERPESVIRUS 6A
17 -36.7375 WTLGLFQVSHGIF HUMAN HERPESVIRUS 8
18 -36.7405 LLSPLPMTPEPTL HUMAN HERPESVIRUS 6B
19 -36.7474 TVQGPFSAACGLF HUMAN ADENOVIRUS A/F
20 -36.7475 TPMPPPQGPPTAM HUMAN HERPESVIRUS 4
Table S1D: CPL-driven search of the human viral database for SB27 (“Index” peptide sequence in boldface).
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Rank Λ Peptide Viral ID
Sequence
1 -8.8549 SLYNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
2 -9.3363 SLFNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
3 -9.3448 SLYNTVAVL HUMAN IMMUNODEFICIENCY VIRUS 1
4 -9.8261 SLFNTVAVL HUMAN IMMUNODEFICIENCY VIRUS 1
5 -10.006 SLYNTIAVL HUMAN IMMUNODEFICIENCY VIRUS 1
6 -10.676 SLFNTIVVL HUMAN IMMUNODEFICIENCY VIRUS 1
7 -11.038 SLHNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
8 -12.608 SLYNAVATL HUMAN IMMUNODEFICIENCY VIRUS 1
9 -13.286 SLYNAVVVL HUMAN IMMUNODEFICIENCY VIRUS 1
10 -13.452 SLFNTTAIV HUMAN IMMUNODEFICIENCY VIRUS 1
11 -14.216 SIDNTVATL HUMAN PAPILLOMAVIRUS
12 -14.397 SLWNAIAVL HUMAN IMMUNODEFICIENCY VIRUS 1
13 -14.531 TIFNTLLTL ROTAVIRUS A
14 -14.586 SLWNAIVVL HUMAN IMMUNODEFICIENCY VIRUS 1
15 -14.599 SMFNKVAVL ROTAVIRUS A
16 -14.633 SLFNLVAVL HUMAN IMMUNODEFICIENCY VIRUS 1
17 -14.669 SLGNTHVAM HUMAN IMMUNODEFICIENCY VIRUS 1
18 -15.021 SMFNKVAIL ROTAVIRUS A
19 -15.249 SLYNTVCVI HUMAN IMMUNODEFICIENCY VIRUS 2
20 -15.335 QVYNTAIIL YABA-LIKE DISEASE VIRUS
Table S1E: CPL-driven search of the human viral database for 003 (“Index” peptide sequence in boldface).
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Rank Λ Peptide Viral ID
Sequence
1 -15.1273 SLYNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
2 -15.2083 SLYNAVATL HUMAN IMMUNODEFICIENCY VIRUS 1
3 -15.5765 SLYNTVAVL HUMAN IMMUNODEFICIENCY VIRUS 1
4 -15.8067 SSYGAPPAP SAPOVIRUS
5 -15.8858 SLYNTIAVL HUMAN IMMUNODEFICIENCY VIRUS 1
6 -15.8864 SLFNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
7 -16.3355 SLFNTVAVL HUMAN IMMUNODEFICIENCY VIRUS 1
8 -16.4996 VLYNFVSTP SAIMIRIINE HERPESVIRUS 2
9 -16.5179 SLYNALAVL HUMAN IMMUNODEFICIENCY VIRUS 1
10 -16.7137 ASYGAPPAP SAPOVIRUS
11 -16.9083 TTFAAVAAV COXSACKIEVIRUS A24
12 -16.957 SVYNFLSKT MONKEYPOX VIRUS,
VACCINIA VIRUS,
VARIOLA VIRUS
13 -17.0372 SIFNIVPRT MONKEYPOX VIRUS,
VACCINIA VIRUS,
VARIOLA VIRUS
14 -17.1894 SLHNTVATL HUMAN IMMUNODEFICIENCY VIRUS 1
15 -17.2614 TGYYAVPTV HUMAN HERPESVIRUS 6A
16 -17.3227 SNYLQPPRL HUMAN HERPESVIRUS 3
17 -17.4171 AMYNSVPLV CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS
18 -17.4273 TGYNFPHKL HUMAN PAPILLOMAVIRUS
19 -17.4426 TTYLALMAT DENGUE VIRUS 1
20 -17.496 TPYNFIAKN VACCINIA VIRUS
Table S1F: CPL-driven search of the human viral database for 868 (“Index” peptide sequence in bold face).
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Rank Λ Peptide Human Self Protein ID
Sequence
1 -13.8709 LSGKWLMHL UPF0696 protein C11orf68
2 -14.6509 LTQKWCHTL F-box/LRR-repeat protein 6
3 -14.7419 LLGKFCTTF cubilin precursor
4 -14.9425 IILKFLARI semaphorin-6A
5 -14.9697 LLGLFLFQL semaphorin-4A
6 -15.006 MTGKFCIIL olfactory receptor 11H6
7 -15.1703 IIGKFCTAL phospholipase A1 member A
8 -15.2091 ILAKFLHWL telomerase reverse transcriptase
9 -15.3153 LTGAFLFSL ATP-sensitive inward rectiﬁer potassium channel 10/15
10 -15.4063 LQGLFLFSL dynein heavy chain 3, axonemal
11 -15.4983 NIGKFLNRI protein strawberry notch homolog
12 -15.5045 IIGKFQFTV protein-glutamine gamma-glutamyltransferase K
13 -15.5077 ITRKHLWRL coiled-coil domain-containing protein 108
14 -15.5221 MVGKFGVTA Solute carrier family 22
15 -15.54 MSGWFLRRT Putative DNA repair and recombination protein RAD26
16 -15.5526 ILGKHGFFV phosphoglucomutase-1
17 -15.5801 FLGKSLFSL epidermal retinol dehydrogenase 2
18 -15.6492 MLGLFLYSL otoferlin
19 -15.6538 MTGLWIFTI N-formyl peptide receptor 3
20 -15.7099 LIQKHLVRL E3 ubiquitin-protein ligase UBR1
Table S2A: CPL-driven search of the human self database for ILA1 (“Index” peptide sequence in boldface).
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Rank Λ Peptide Human Self Protein ID
Sequence
1 -16.8944 LLAGIGTVPI solute carrier organic anion transporter
2 -17.418 ILEGIGILAV anoctamin-3
3 -17.5337 LLLGIGILVL bone marrow stromal antigen 2
4 -17.6102 FLAGLGLLVI translocon-associated protein subunit alpha
5 -17.6562 AAAAIFVIII MHC class I polypeptide-related sequence A
6 -17.7312 FVAGIFLLVV protocadherin Fat 1 precursor
7 -17.9409 FITGKGIVAI leiomodin-3
8 -18.0041 LITGLGIISV adenosine receptor A3
9 -18.013 ILLGIGIYAL transmembrane and coiled-coil domain-containing protein 2
10 -18.0426 LLAGLGILAG provirus ancestral Env polyprotein preproprotein
11 -18.1265 ISAAIWIVVG putative P2Y purinoceptor 10
12 -18.1456 IAAGTGIVIL transmembrane 7 superfamily member 4
13 -18.228 FITATGVVKL serine/threonine-protein kinase Nek6
14 -18.2536 ITAGLPVKVV amyloid protein-binding protein 2
15 -18.2816 LKTGIGVIRM neuropilin and tolloid-like protein 2 precursor
16 -18.3184 SLTGLGVVKV E3 ubiquitin-protein ligase HERC2
17 -18.3348 WTAPIGVISL uncharacterized protein C5orf4
18 -18.3916 FITGTGILAL tropomodulin-2
19 -18.399 AGTGIGLMVL intermediate conductance calcium-activated potassium channel protein 4
20 -18.4265 ILEGIGILSV anoctamin-4
Table S2B: CPL-driven search of the human self database for MEL5 (EAAGIGILTV ranked 55).
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